TBI combined with cyclophosphamide (CY) is among the most common myeloablative conditioning regimens used in conjunction with allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of various hematological malignancies. 1, 2 In a mouse model of transplantation, donor lymphocyte infusion immediately after TBI was associated with a significantly higher incidence of acute GvHD when compared with delayed donor lymphocyte infusion after TBI, 3 a finding that might be explained by differences in the levels of inflammatory cytokines induced by TBI at the time of donor cell infusion. Specifically, the cytokine levels should have been higher in animals treated with TBI immediately before donor cell infusion, and the cytokines would thus have contributed more significantly to donor T-cell activation. [4] [5] [6] In pediatric patients subjected to conditioning regimens for allogeneic HSCT, the administration of TBI before high-dose chemotherapy has been reported to lead to an increased risk of acute GvHD. 7 However, it remains unclear whether the order of TBI and CY administration affects transplantassociated complications and transplant outcomes in adults. The purpose of this study was to clarify the effect of the order of TBI and CY administration on the outcome of allogeneic HSCT.
We retrospectively investigated the transplant outcomes of consecutive patients with AML, ALL and myelodysplastic syndrome (MDS) who underwent initial allogeneic HSCT with myeloablative conditioning regimens comprising TBI and CY between 1 January 2001 and 31 August 2012 at 20 institutes in Japan participating in the Kanto Study Group for Cell Therapy. Although patients who received cord blood units were included regardless of the degree of HLA disparity, 126 patients who received HLA-mismatched grafts from related or unrelated donors were excluded. Patients who received conditioning agents such as cytarabine, thiotepa and etoposide in addition to CY and TBI and those subjected to ex vivo or in vivo T-cell depletion were excluded. This study was approved by the institutional review board of Yokohama City University Medical Center. The trial was conducted in accordance with the Declaration of Helsinki.
CY was given at a dosage of 60 mg/kg/day for 2 days. All patients were subjected to a fractionated TBI schedule. The number of TBI fractions and the irradiation method were selected according to the policy of each institute. The conditioning regimens were categorized into two groups with respect to the order of administration: TBI after CY (CY-TBI) and TBI before CY (TBI-CY). Although one institute used only the CY-TBI regimen and three institutes used only the TBI-CY regimen, other institutions occasionally selected the administration order according to the day of transplantation and/or the availability of TBI; the latter was performed only on weekdays. Acute leukemia in first or second remission and refractory anemia (MDS) were considered standardrisk diseases; all other conditions were considered high-risk diseases. Acute and chronic GvHD were graded by the attending physicians according to traditional criteria. 8, 9 The patient and transplantation characteristics are summarized in Table 1 . A total of 504 patients were included in the study; among them, 218 received CY-TBI, and 286 received TBI-CY. The median follow-up durations were 21.1 months (range, 1.5-136 months) in the CY-TBI group and 21.6 months (range, 0.2-136.8 months) in the TBI-CY group. Neutrophil engraftment was achieved in 200 (91.7%) of 218 patients in the CY-TBI group and in 265 (92.7%) of 286 patients in the TBI-CY group. The median time to neutrophil recovery did not significantly differ between the two groups, with periods of 18 days (range, 11-53 days) in the CY-TBI group and 17 days (range, 9-49 days) in the TBI-CY group (P = 0.51). Of the 39 patients who did not achieve engraftment, 25 underwent cord blood transplantation, and 12 died within 30 days after transplantation.
The cumulative incidence rates of grade 2-4 acute GvHD were 45.3% and 49.3% for patients undergoing transplantation with the CY-TBI and TBI-CY regimens, respectively (P = 0.28). The cumulative incidence rates of grade 3-4 acute GvHD in the same groups were 14.6% and 11.3%, respectively (P = 0.59). In addition, the cumulative incidence rates of limited and extensive chronic GvHD in these groups at 2 years after transplantation were 36.0% and 43.8%, respectively (P = 0.10). In a multivariate analysis, the risks of grade 2-4 and 3-4 acute GvHD were comparable in the two groups (hazard ratio (HR), 1.11; 95% confidence interval (CI), 0.83-1.47; P = 0.49 and HR, 0.92; 95% CI, 0.52-1.63; P = 0.77)), respectively; however, the risk of chronic GvHD, which included both the limited and extensive types, tended to be lower in the CY-TBI group (HR, 1.35; 95% CI, 0.99-1.86; P = 0.06). The order of TBI and CY administration had no significant association with the risks of acute and chronic GvHD. The cumulative incidence rates of sinusoidal obstruction syndrome at 30 days were 4.1% in the CY-TBI group and 3.8% in the TBI-CY group (P = 0.81). In the same groups, the respective cumulative incidence rates of idiopathic pneumonia at 2 years were 3.1% and 3.4% (P = 0.87). Similarly, the 5-year nonrelapse mortality (NRM) rates did not significantly differ between the two groups (19.3% in the CY-TBI group vs 16.7% in the TBI-CY group; P = 0.52). In a multivariate analysis, the NRM risk was comparable between the two groups (HR, 1.08; 95% CI, 0.66-1.78; P = 0.76). The 5-year cumulative incidences of relapse in the CY-TBI and TBI-CY groups were comparable (30.2% vs 31.8%, respectively; P = 0.96). Accordingly, the relapse risk was similar in the two groups in a multivariate analysis (HR, 1.15; 95% CI, 0.82-1.62; P = 0.42). The adjusted 5-year disease-free survival (DFS) rates were also similar at 54.9% in the CY-TBI group and 49.6% in the TBI-CY group (P = 0.71). The adjusted 5-year overall survival (OS) rates were also similar at 58.1% in the CY-TBI group and 52.0% in the TBI-CY group (P = 0.57). A multivariate analysis revealed that the order of TBI and CY administration had no significant impact on DFS (HR, 1.05; 95% CI, 0.80-1.38; P = 0.71) or OS (HR, 1.09; 95% CI, 0.82-1.45; P = 0.57).
Among standard-risk patients, the cumulative 5-year relapse rates were 17.5% in the CY-TBI group and 27.6% in the TBI-CY group (P = 0.044; Figure 1a) . A multivariate analysis revealed a lower cumulative relapse rate in the CY-TBI group relative to the TBI-CY group (HR, 1.62; 95% CI: 0.97-2.71; P = 0.066) although this difference was not statistically significant. NRM, DFS and OS were comparable between the groups (Figures 1b-d) . Among high-risk patients, the cumulative 5-year relapse rates were similar in the CY-TBI and TBI-CY groups (51.8% vs 46.5%; P = 0.50). NRM, DFS and OS were also comparable between the groups.
The findings of this retrospective study demonstrated that the order of TBI and CY administration did not significantly affect the outcomes of transplantation. In a mouse model, lymphocyte infusion immediately after TBI was significantly associated with an increased incidence of acute GvHD relative to that observed when lymphocyte infusion after TBI was delayed. 3 Inflammatory cytokines induced by TBI, such as tumor necrosis factor α and interleukin-1, have been associated with the development of GvHD. [3] [4] [5] [6] We hypothesized that compared with TBI-CY, CY-TBI was more likely to induce cytokines and thus directly affect donorderived lymphocytes and increase the incidence of GvHD. However, the incidence of GvHD was comparable in both groups. This finding may be attributable to the fact that in humans, calcineurin inhibitors are used as GvHD prophylaxis in nearly all cases and, therefore, GvHD may be well controlled. Another concern is that some institutions administer steroids during TBI to prevent emesis, a factor that may also affect the outcome. In our study, a univariate analysis revealed a lower relapse rate only in Letter to the Editor CY-TBI group patients with standard-risk disease. The multivariate analysis revealed a tendency toward a reduced relapse rate among CY-TBI group patients with standard-risk disease, although there was no significant difference between the two groups. In the CY-TBI group, minimum residual disease might have been eradicated by TBI after CY; however, the true mechanism remains unknown. Recently, Holter-Chakrabarty et al. 10 used data from the Center for International Blood and Marrow Transplant Research to report that the CY and TBI administration sequence did not impact transplant outcomes and complications. This study had some limitations, including its observational retrospective design, disparities in institutional practices and small number of analyzed patients. The irradiation equipment and method differed among the institutes, and accordingly there may be some inter-institutional differences. As we focused on the order of TBI and CY administration, the time intervals from TBI to transplantation varied widely even within single groups. In conclusion, patients undergoing allogeneic HSCT can receive TBI and CY in either order, as the order of TBI and CY administration does not appear to affect the outcome of allogeneic HSCT in a clinical practice setting. However, a prospective randomized multicenter study is warranted to confirm our findings. 
